What Cetrorelix is
Cetrorelix is a GnRH antagonist peptide used in approved fertility-medicine contexts.
Cetrorelix is grouped under Approved / Clinical / Endogenous / Biology on PeptideFactCheck because it is part of the same real peptide-medicine family as ganirelix and degarelix.
The useful starting point is to separate the molecule itself from the internet story around it. It is part of the same real peptide-medicine family as ganirelix and degarelix.
Why people keep looking it up
It is part of the same real peptide-medicine family as ganirelix and degarelix.
Cetrorelix is a GnRH antagonist peptide used in approved fertility-medicine contexts.
Cetrorelix tends to stay in the conversation because it touches a familiar public theme: gnrh antagonist, fertility medicine, and pituitary signaling. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved peptide antagonist with direct human evidence.
Human trials and official labeling support specific approved uses.
Mechanistic support follows direct GnRH antagonism.
Why this page carries the current tier: Approved peptide antagonist with direct human evidence.
The current seed trail for Cetrorelix is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
This is a tightly defined clinical endocrine use case, not a general hormone hack.
FDA-approved cetrorelix products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Cetrorelix. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Cetrorelix is CID 25074887. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 25074887
- Formula
- C70H92ClN17O14
- Molecular weight
- 1431.0
- InChIKey
- SBNPWPIBESPSIF-MHWMIDJBSA-N
Matched synonyms include Cetrorelix, 120287-85-6, Cetrorelixum, OON1HFZ4BA, SB-75, DTXSID7040996, CHEBI:59224, N-Acetyl-3-(2-naphthyl)-D-alanyl-p-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N(sup 5)-carbamoyl-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Cetrorelix returns 137 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Cetrorelix returns 805 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- cetrorelix acetate
- Generic names
- CETRORELIX ACETATE
- Routes
- Not linked
- Application numbers
- ANDA218150
Indications and usage. INDICATIONS AND USAGE Cetrorelix acetate for injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
Contraindications. CONTRAINDICATIONS Cetrorelix acetate for injection is contraindicated under the following conditions: 1. Hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol. 2. Known hypersensitivity to GnRH or any other GnRH analogs. 3. Known or suspected pregnancy, and lactation (see PRECAUTIONS). 4. Severe renal impairment.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.